Psyence BioMed Announces Strategic Ibogaine Investment

Transactions include an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchangeHighlightsNEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. NASDAQ:PBM (“Psyence BioMed” or the “Company”), a biopharmaceutical company developing nat…